|View printer-friendly version|
Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
“We are excited to present impressive data on our chimeric antisense oligonucleotide (CASO) program in HBV, including our preclinical candidate, SB 527, at HepDART 2019,” commented Dr. Radhakrishnan Iyer, Co-Founder and Chief Scientific Officer of
Poster Presentation #P14
Title: “Antisense Oligonucleotide Linked to an Immunomodulatory Dinucleotide are Highly Potent Anti-HBV Agents,” by Dr. Lakshmi Bhagat, Discovery Group Leader – Immunology
Summary: Spring Bank’s lead CASOs potently inhibit HBV DNA, HBsAg and HBeAg via a gene silencing mechanism as well as the intracellular release of an immunomodulator from the CASOs.
Poster Presentation #P5
Title: “The Anti-HBV Dinucleotide Inarigivir is a Novel RIG-I Agonist – MOA Studies,” by Dr. Radhakrishnan Iyer, Co-Founder and Chief Scientific Officer
Summary: Preclinical results demonstrate that inarigivir activates the innate immune receptor RIG-I to produce interferons and cytokines for antiviral defense. These preclinical results further validate the mechanism of action and the observed antiviral efficacy of inarigivir in HBV patients.
Following these presentations, the posters will be available on the Publications page of the company’s website.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, about Spring Bank’s future expectations, plans and prospects. These statements include, but are not limited to, statements about the company’s plans to develop a triplet therapeutic modality and the potential timing for conducting IND-enabling toxicology studies and being IND/CTA-ready for its CASOs. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “will,” “would,” “could,” “potential,” “possible,” “hope,” “likelihood” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: Spring Bank’s ability to successfully demonstrate the safety and efficacy of its product candidates; any delay of any current or planned non-clinical or clinical trials or the development of any product candidate; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of such trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
McNeil, Gray & Rice
Source: Spring Bank Pharmaceuticals, Inc.